Evidence map›Paper›PMID 31324785›Full record

ArticleNature communications2019

Acetylation regulates ribonucleotide reductase activity and cancer cell growth.

Guo Chen, Yin Luo, Kurt Warncke, Youwei Sun, David S Yu, Haian Fu, Madhusmita Behera, Suresh S Ramalingam, Paul W Doetsch, Duc M Duong and 3 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 79 citations in OpenAlex.

  1. Research progress on lysine acetylation (Review).International journal of molecular medicine · 2026
    Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. DEAD/H-box RNA helicase 10 promotes pancreatic cancer cell proliferationWorld journal of gastrointestinal oncology · 2025
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Role of BRCA1 in glioblastoma etiology.Cellular oncology (Dordrecht, Netherlands) · 2024
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 3 countries.

Guo ChenDepartments of Radiation Oncology, Emory University School of Medicine and Winship Cancer Institute of Emory University, 1365C Clifton Road NE, Atlanta, GA, 30322, USA.
Yin LuoDepartment of Pharmacology, Emory University School of Medicine and Winship Cancer Institute of Emory University, 1510 Clifton Rd. NE, Atlanta, GA, 30322, USA.
Kurt WarnckeDepartment of Physics, Emory University, 400 Dowman Drive, Atlanta, GA, 30322, USA.
Youwei SunDepartments of Radiation Oncology, Emory University School of Medicine and Winship Cancer Institute of Emory University, 1365C Clifton Road NE, Atlanta, GA, 30322, USA.
David S YuDepartments of Radiation Oncology, Emory University School of Medicine and Winship Cancer Institute of Emory University, 1365C Clifton Road NE, Atlanta, GA, 30322, USA.
Haian FuDepartment of Pharmacology, Emory University School of Medicine and Winship Cancer Institute of Emory University, 1510 Clifton Rd. NE, Atlanta, GA, 30322, USA.ORCID http://orcid.org/0000-0002-2362-7979
Madhusmita BeheraDepartment of Hematology and Medical Oncology, Emory University School of Medicine and Winship Cancer Institute of Emory University, 1365C Clifton Road NE, Atlanta, GA, 30322, USA.
Suresh S RamalingamDepartment of Hematology and Medical Oncology, Emory University School of Medicine and Winship Cancer Institute of Emory University, 1365C Clifton Road NE, Atlanta, GA, 30322, USA.
Paul W DoetschLaboratory of Genome Integrity and Structural Biology, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC, 27709, USA.
Duc M DuongDepartment of Biochemistry, Emory University School of Medicine, 1510 Clifton Rd. NE, Atlanta, GA, 30322, USA.
Michael LammersInstitute of Biochemistry, Synthetic and Structural Biochemistry, University of Greifswald, Felix-Hausdorff-Str. 4, Greifswald, 17487, Germany.
Walter J CurranDepartments of Radiation Oncology, Emory University School of Medicine and Winship Cancer Institute of Emory University, 1365C Clifton Road NE, Atlanta, GA, 30322, USA.
Xingming DengDepartments of Radiation Oncology, Emory University School of Medicine and Winship Cancer Institute of Emory University, 1365C Clifton Road NE, Atlanta, GA, 30322, USA. xdeng4@emory.edu.
Emory University · USNational Institutes of Health · USUniversität Greifswald · DE

Funding

Mechanisms of transcriptional and replicative mutagenesisZIAES103328 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI DOETSCH, PAUL · 2018 to 2025
$10.5M
Systematic discovery of neomorph protein-protein interactions in cancer for oncogenic pathway perturbationU01CA217875 · NCI · EMORY UNIVERSITY · PI FU, HAIAN · 2017 to 2021
$4.5M
Co(II)-Radical Pair Dynamics in B12 Enzyme CatalysisR01DK054514 · NIDDK · EMORY UNIVERSITY · PI WARNCKE, KURT · 1998 to 2019
$4.2M
Mechanisms of SIRT2 Function in the Replication Stress ResponseR01CA178999 · NCI · EMORY UNIVERSITY · PI YU, DAVID SUNG-WEN · 2013 to 2023
$3.5M
Structure-based anti-cancer drug developmentR01CA136534 · NCI · EMORY UNIVERSITY · PI DENG, XINGMING · 2010 to 2020
$3.4M
Modulation of BAK in Lung Cancer TherapeuticsR01CA200905 · NCI · EMORY UNIVERSITY · PI DENG, XINGMING · 2017 to 2021
$1.8M
Modulation of Bcl2 BH4 and mTOR in lung cancer therapeuticsR01CA193828 · NCI · EMORY UNIVERSITY · PI DENG, XINGMING · 2015 to 2019
$1.8M
NCI NIH HHS R01 CA136534NCI NIH HHS R01 CA178999NCI NIH HHS R01 CA193828NCI NIH HHS R01 CA200905NCI NIH HHS U01 CA217875NIDDK NIH HHS R01 DK054514
6 · The paper itself

Abstract

Ribonucleotide reductase (RNR) catalyzes the de novo synthesis of deoxyribonucleoside diphosphates (dNDPs) to provide dNTP precursors for DNA synthesis. Here, we report that acetylation and deacetylation of the RRM2 subunit of RNR acts as a molecular switch that impacts RNR activity, dNTP synthesis, and DNA replication fork progression. Acetylation of RRM2 at K95 abrogates RNR activity by disrupting its homodimer assembly. RRM2 is directly acetylated by KAT7, and deacetylated by Sirt2, respectively. Sirt2, which level peak in S phase, sustains RNR activity at or above a threshold level required for dNTPs synthesis. We also find that radiation or camptothecin-induced DNA damage promotes RRM2 deacetylation by enhancing Sirt2-RRM2 interaction. Acetylation of RRM2 at K95 results in the reduction of the dNTP pool, DNA replication fork stalling, and the suppression of tumor cell growth in vitro and in vivo. This study therefore identifies acetylation as a regulatory mechanism governing RNR activity.

Indexed as

AcetylationCamptothecinCell CycleCell Line, TumorCell Transformation, NeoplasticDNA DamageDNA ReplicationGene Expression Regulation, NeoplasticHistone AcetyltransferasesHumansRibonucleoside Diphosphate ReductaseRibonucleotide ReductasesSirtuin 2S PhaseCamptothecinHistone AcetyltransferasesKAT7 protein, humanRibonucleoside Diphosphate Reductaseribonucleotide reductase M2Ribonucleotide ReductasesSIRT2 protein, humanSirtuin 2

Identifiers

PMID31324785
PMCPMC6642173
OpenAlexW2963368358

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.